Drug Profile
Research programme: diclofenac foam - Foamix
Alternative Names: Diclofenac 1% foam - Foamix; Diclofenac 3% foam - Foamix; DicloFoam 1%; DicloFoam 3%Latest Information Update: 17 Dec 2021
Price :
$50
*
At a glance
- Originator Foamix
- Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Actinic keratosis; Musculoskeletal pain; Osteoarthritis
Most Recent Events
- 09 Mar 2020 Foamix has been acquired by Menlo Therapeutics
- 27 Jan 2011 Preclinical development is ongoing in Israel
- 12 Sep 2005 Diclofenac foam is available for licensing (http://www.foamix.co.il)